GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Piotroski F-Score

iBio (IBIO) Piotroski F-Score : 4 (As of May. 30, 2024)


View and export this data going back to 2008. Start your Free Trial

What is iBio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

iBio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for iBio's Piotroski F-Score or its related term are showing as below:

IBIO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of iBio was 5. The lowest was 1. And the median was 3.


iBio Piotroski F-Score Historical Data

The historical data trend for iBio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Piotroski F-Score Chart

iBio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 3.00 3.00 1.00

iBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 1.00 2.00 4.00

Competitive Comparison of iBio's Piotroski F-Score

For the Biotechnology subindustry, iBio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where iBio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -6.033 + -5.746 + -8.211 + -3.172 = $-23.16 Mil.
Cash Flow from Operations was -4.97 + -5.34 + -4.706 + -3.654 = $-18.67 Mil.
Revenue was 0 + 0.05 + 0 + 0 = $0.05 Mil.
Gross Profit was 0 + 0.05 + 0 + 0 = $0.05 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(44.386 + 41.207 + 37.678 + 34.022 + 50.154) / 5 = $41.4894 Mil.
Total Assets at the begining of this year (Mar23) was $44.39 Mil.
Long-Term Debt & Capital Lease Obligation was $3.76 Mil.
Total Current Assets was $36.14 Mil.
Total Current Liabilities was $21.43 Mil.
Net Income was -17.142 + -18.13 + -33.553 + -7.294 = $-76.12 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0.046 + 0 + 0 + 0 = $0.05 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(115.37 + 99.406 + 84.564 + 51.8 + 44.386) / 5 = $79.1052 Mil.
Total Assets at the begining of last year (Mar22) was $115.37 Mil.
Long-Term Debt & Capital Lease Obligation was $3.65 Mil.
Total Current Assets was $27.09 Mil.
Total Current Liabilities was $22.28 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

iBio's current Net Income (TTM) was -23.16. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

iBio's current Cash Flow from Operations (TTM) was -18.67. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-23.162/44.386
=-0.52183121

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-76.119/115.37
=-0.65978157

iBio's return on assets of this year was -0.52183121. iBio's return on assets of last year was -0.65978157. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

iBio's current Net Income (TTM) was -23.16. iBio's current Cash Flow from Operations (TTM) was -18.67. ==> -18.67 > -23.16 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=3.755/41.4894
=0.09050504

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=3.647/79.1052
=0.04610316

iBio's gearing of this year was 0.09050504. iBio's gearing of last year was 0.04610316. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=36.139/21.426
=1.68668907

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=27.093/22.276
=1.2162417

iBio's current ratio of this year was 1.68668907. iBio's current ratio of last year was 1.2162417. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

iBio's number of shares in issue this year was 3.713. iBio's number of shares in issue last year was 0.659. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.05/0.05
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.046/0
=

iBio's gross margin of this year was 1. iBio's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=0.05/44.386
=0.00112648

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=0/115.37
=0

iBio's asset turnover of this year was 0.00112648. iBio's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

iBio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

iBio  (AMEX:IBIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


iBio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of iBio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


iBio (IBIO) Business Description

Traded in Other Exchanges
N/A
Address
8800 HSC Parkway, Bryan, TX, USA, 77807-1107
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
Executives
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431